Thomas C. Harding - 01 Sep 2021 Form 4 Insider Report for Clovis Oncology, Inc.

Role
Senior Vice President and Chief Scientific Officer
Signature
/s/ Thomas Harding
Issuer symbol
N/A
Transactions as of
01 Sep 2021
Net transactions value
-$724
Form type
4
Filing time
03 Sep 2021, 17:21:00 UTC
Previous filing
03 Aug 2021
Next filing
05 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLVS Common Stock Options Exercise +281 +8.2% 3,704 01 Sep 2021 Direct F1
transaction CLVS Common Stock Sale $689 -141 -3.8% $4.89* 3,563 02 Sep 2021 Direct F2
transaction CLVS Common Stock Options Exercise +19 +1.4% 1,410 01 Sep 2021 By wife F1
transaction CLVS Common Stock Sale $34.23 -7 -0.5% $4.89* 1,403 02 Sep 2021 By wife F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLVS Restricted Stock Units Options Exercise $0 -281 -33% $0.000000 563 01 Sep 2021 Common Stock 281 Direct F1, F3
transaction CLVS Restricted Stock Units Options Exercise $0 -19 -34% $0.000000 37 01 Sep 2021 Common Stock 19 By wife F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2 Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3 On March 1, 2018, the reporting person was granted 4,500 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
F4 On March 1, 2018, the reporting person was granted 297 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

Remarks:

Senior Vice President and Chief Scientific Officer